RP Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

RP Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,111,111	Closed	-$168M	–	4
2022 Q3	$168M	Hold	1,111,111	–	–	77.6%	1
2022 Q2	$162M	Hold	1,111,111	–	–	63.94%	1
2022 Q1	$132M	Hold	1,111,111	–	–	53.58%	1
2021 Q4	$153M	Hold	1,111,111	–	–	64.09%	1
2021 Q3	$154M	Hold	1,111,111	–	–	72.03%	1
2021 Q2	$108M	Sell	1,111,111 -1,000,000	-47%	-$81.2M	52.6%	1
2021 Q1	$144M	Hold	2,111,111	–	–	54.16%	1
2020 Q4	$181M	Hold	2,111,111	–	–	55.51%	1
2020 Q3	$137M	Hold	2,111,111	–	–	20.57%	2
2020 Q2	$154M	Hold	2,111,111	–	–	29.83%	2
2020 Q1	$71.8M	Hold	2,111,111	–	–	22.3%	2
2019 Q4	$115M	Hold	2,111,111	–	–	25.98%	2
2019 Q3	$88.1M	Hold	2,111,111	–	–	56.41%	1
2019 Q2	$92.4M	Hold	2,111,111	–	–	56.7%	1
2019 Q1	$109M	Hold	2,111,111	–	–	54.35%	1
2018 Q4	$78.1M	Buy	+2,111,111	New	+$76.1M	53.45%	1

Other funds holding BHVN

LIP

Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MSCM

McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

RP Management's BHVN Position: Q4 2022 in Review

RP Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,111,111 shares — an estimated $168M sold.

RP Management first reported a position in BHVN in Q4 2018 and held it in 16 quarters. The position peaked at $181M in Q4 2020. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

RP Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
RP Management sold 1,111,111 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $168M.
RP Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 16 quarters.
RP Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $181M in Q4 2020.
7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on RP Management's 13F filing for Q4 2022, filed 14 Feb 2023.